Jump to content

Penumbra (medical company)

From Alfawiki
Adapted from the English Wikipedia article Penumbra (medical company), available under CC BY-SA 4.0Updated 25 July 2025
Penumbra, Inc.
Company typePublic
IndustryMedical devices
Founded2004; 22 years ago (2004)
FounderArani Bose, Adam Elsesser
Headquarters
Alameda, California
,
United States
Area served
Worldwide
ProductsInterventional tools for vascular disorders (stroke, aneurysm)
Number of employees
4,200 (2024)

Penumbra, Inc. is a U.S.-based medical device manufacturer headquartered in Alameda, California. Established in 2004 by entrepreneurs Arani Bose and Adam Elsesser, the firm concentrates on interventional tools designed to address vascular disorders such as stroke and aneurysm. As of 2024, Penumbra employs around 4,200 individuals worldwide.

History

From its inception, Penumbra has concentrated on the neurovascular sector, creating solutions aimed at treating ischemic stroke and aneurysms. In 2014, the company introduced the Apollo system, a minimally invasive technology intended to extract deeply located brain clots and tissue that were previously deemed untreatable.

Penumbra became a publicly traded company on the New York Stock Exchange in 2015, which bolstered its financial standing and visibility in the market. The company also pursued growth through acquisitions, including acquiring a controlling interest in virtual reality firm MVI Health in 2018 and purchasing Italian distributor Crossmed in 2017, thereby strengthening its international distribution capabilities.

Criticism

The company has encountered criticism concerning both its product safety and corporate conduct. In 2016, litigation was initiated claiming that the Penumbra Coil 400 led to brain injuries following surgical procedures. Additionally, its specialized catheter was associated with fatalities among stroke patients, attracting attention from stock short sellers in 2020. These incidents raised significant apprehensions regarding product safety and the firm’s reputation within the market.

Following these developments, calls for examinations by the SEC and U.S. Food and Drug Administration emerged amid allegations that a scientist credited with validating Penumbra’s product efficacy was fictitious. This controversy adversely affected investor trust and financial outcomes, underscoring difficulties in sustaining competitive positioning within the medical device sector.

Recalls

Penumbra has conducted multiple product recalls affecting its range of medical devices. In 2011, the Penumbra Coil 400 was recalled due to safety issues. Another recall in 2017 involved a 3D revascularization device because of potential wire fractures. Most prominently, in 2020, Penumbra voluntarily withdrew its JET 7 catheters featuring Xtra Flex technology after reports indicated heightened risks of death and severe injury during cardiac surgeries. These recall events have shaped the company’s approach to risk management and adherence to regulatory standards in the medical technology field.